- Languages required Dutch, English
- Open to remote working? No
Looking for a hands-on co-founder with vision and drive to join the adventure of turning a successful research project into a booming pharmaceutical company. The project showed the possibility of producing certain biomedical compounds with the use of wastewater treatment technologies in a reliable, safe and innovative way. Focus at the moment lies on using found compounds as a treatment for sepsis. The available role encompasses design and strategic planning of the R&D activities to further define the chemical footprint of the compound and purification of the compound that meets clinical trial standards. Until the team has grown sufficiently, you are also expected to perform a part of the lab activities.
- Why we do it: Sepsis is responsible for 1 in 5 deaths worldwide. At the moment there is no widely available treatment that works on all pathogen sources during all stages of sepsis. We believe that with this compound we can create a reliable and scalable treatment for sepsis originating from not only bacteria but also from viruses and fungi. This would mean potentially being able to save millions of lives per year!
- Who are we: Small, enthusiastic, ambitious team that believes in the potential of this technology platform. Team members come from diverse backgrounds and are excited about developing themselves both in their own field and in that of their colleagues. Passionate about making the world a better place and contributing to reaching at least one of the 17 global goals.
- Who are you: Analytical, entrepreneurial mind who is excited about design an execution of wetlab work and wants to shape this process and company to their vision. Preferably master or PhD level in biotechnology, (bio)chemistry, medicinal chemistry or any other relevant field. Able to grow into a more managerial role as the team grows. Doubts about your background? Just ask!
- About the technology: The idea originates from the department of Environmental Biotechnology, where amongst others dr Mark van Loosdrecht (advisory board) and dr Yuemei Lin (advisory board) have developed and patented a novel way of producing heparin-like polymers from Aerobic Granular Sludge (AGS). The sludge granules consist of bacteria embedded in a matrix of extracellular polymeric substances (EPS). Research has shown that, with the use of these slow growing organisms, the EPS of sea-water adapted AGS contains various biomedical substances, including (sulfated) glycosaminoglycans (GAGs). A percentage of these glycosaminoglycans were proven to be non-anticoagulating heparin-like biopolymers. In another study, similar compounds extracted from less favorable (bottle neck) resources already showed very promising effects in the treatment of sepsis in mice models.
- Rewards: Shares & salary
- Location: For at least the coming year and a half at the Delft University of Technology.
- Contact: Winnifred Noorlander, firstname.lastname@example.org
- Salary Offer €20 - 40,000
- Address van der maasweg 9